Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 3

Predictors of adherence to physical activity in the Lifestyle Interventions and Independence for Elders pilot study (LIFE-P)

Authors W Jack Rejeski, Michael E Miller, Abby C King, Stephanie A Studenski, Jeffrey A Katula, et al For the LIFE Investigators (2006)

Published 15 October 2007 Volume 2007:2(3) Pages 485—494

W Jack Rejeski1, Michael E Miller2, Abby C King3, Stephanie A Studenski4, Jeffrey A Katula1, Roger A Fielding5, Nancy W Glynn4, Michael P Walkup2, Jamile A Ashmore6, For the LIFE Investigators (2006)

1Department of Health and Exercise Science, Wake Forest University; 2Department of Biostatistics, Wake Forest University; 3Stanford University; 4University of Pittsburgh; 5Tuffs University; 6Cooper Institute

Objectives: A prospective design was used to examine predictors of adherence to a physical activity intervention in older adults with compromised function.

Methods: The sample included 213 men (31.1%) and women (68.9%) with an average age of 76.53 years.

Results: The predictor variables accounted for 10% of the variance in percent attendance during adoption and transition, respectively. Adding percent attendance during adoption to the prediction of percent attendance during transition increased the explained variance in this phase to 21%. During maintenance, the predictors accounted for 13% of the variance in frequency of physical activity; this estimate increased to 46% when adding in percent attendance from the transition phase.

Discussion: These results are encouraging in that the physical activity intervention appears to have been well tolerated by diverse subgroups of older adults. The role of prior behavior in predicting downstream adherence underscores the importance of developing proactive interventions for treating nonadherence in older adult populations.

Keywords: Disability, Physical Activity, Older Adults, Adherence

Download Article [PDF] 

Readers of this article also read:

PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo

Chiang KC, Chen HY, Hsu SY, Pang JHS, Wang SY, Hsu JT, Yeh TS, Chen LW, Kuo SF, Sun CC, Lee JM, Yeh CN, Juang HH

Drug Design, Development and Therapy 2015, 9:4631-4638

Published Date: 13 August 2015

Ophthalmology on social networking sites: an observational study of Facebook, Twitter, and LinkedIn

Micieli JA, Tsui E

Clinical Ophthalmology 2015, 9:285-290

Published Date: 10 February 2015

Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

Schaffran T, Jiang N, Bergmann M, Küstermann E, Süss R, Schubert R, Wagner FM, Awad D, Gabel D

International Journal of Nanomedicine 2014, 9:3583-3590

Published Date: 29 July 2014

Design of indomethacin-loaded nanoparticles: effect of polymer matrix and surfactant

Dupeyrón D, Kawakami M, Ferreira AM, Cáceres-Vélez PR, Rieumont J, Azevedo RB, Carvalho JCT

International Journal of Nanomedicine 2013, 8:3467-3477

Published Date: 13 September 2013

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo

Therapeutics and Clinical Risk Management 2009, 5:187-207

Published Date: 4 March 2009

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily

Claus G Roehrborn, Raymond C Rosen

Clinical Interventions in Aging 2008, 3:511-524

Published Date: 12 September 2008

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Clinical Interventions in Aging 2008, 3:445-451

Published Date: 12 September 2008

Factors that influence exercise activity among women post hip fracture participating in the Exercise Plus Program

Barbara Resnick, Denise Orwig, Christopher D′Adamo, Janet Yu-Yahiro, William Hawkes, et al

Clinical Interventions in Aging 2007, 2:413-427

Published Date: 15 October 2007

Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

Usha Panchapakesan, Siska Sumual, Carol Pollock

International Journal of Nanomedicine 2007, 2:33-38

Published Date: 15 April 2007